医学
阿替唑单抗
贝伐单抗
临床终点
肝细胞癌
内科学
实体瘤疗效评价标准
肿瘤科
无进展生存期
临床研究阶段
阶段(地层学)
索拉非尼
外科
胃肠病学
癌症
临床试验
总体生存率
化疗
无容量
免疫疗法
古生物学
生物
作者
Masatoshi Kudo,Kazuomi Ueshima,Kaoru Tsuchiya,Tatsuya Yamashita,Shigeo Shimose,Kazushi Numata,Yuzo Kodama,Shinji Itoh,Yasuhito Tanaka,Hidekatsu Kuroda,Hiroshi Aikata,Atsushi Hiraoka,Michihisa Moriguchi,Ryosuke Tateishi,Sadahisa Ogasawara,Kouji Yamamoto,Masafumi Ikeda
出处
期刊:Liver cancer
[Karger Publishers]
日期:2025-06-19
卷期号:15 (1): 104-116
被引量:17
摘要
Introduction: Intermediate-stage hepatocellular carcinoma (HCC) presents varying tumor burdens. For patients unsuitable for transcatheter arterial chemoembolization (TACE) due to high tumor burden, recent guidelines recommend systemic therapy. This study evaluates the efficacy and safety of atezolizumab plus bevacizumab for TACE-unsuitable patients with unresectable intermediate-stage HCC beyond up-to-seven criteria. Methods: This prospective, phase II, single-arm, non-blinded study enrolled TACE-naïve patients with unresectable intermediate-stage HCC beyond up-to-seven criteria, Child-Pugh A, no previous systemic therapy, and ECOG Performance Status score of 0–1 from 35 sites in Japan. Patients received atezolizumab 1,200 mg and bevacizumab 15 mg/kg every 3 weeks. The primary endpoint was the 6-month progression-free survival (PFS) rate by modified RECIST (mRECIST). Key secondary endpoints included the objective response rate (ORR) and safety. Exploratory endpoints examined individual changes in tumor size, comparison by inverse probability weighting (IPW) of data with retrospective historical data of TACE-treated patients, and conversion rate to a curative intent therapy. Results: In total, 74 patients were enrolled from December 2020 to September 2021 (median follow-up, 15.1 months). The 6-month PFS rate by mRECIST was 66.8% (90% CI: 56.8, 75.0), and the lower limit of the 90% CI exceeded the pre-specified threshold of 55%. ORR by mRECIST was 40.5%. After treatment with atezolizumab plus bevacizumab, 10 patients, including 5 patients who had a tumor burden beyond the up-to-11 criteria at baseline, were able to transition to curative intent therapy. PFS by mRECIST by IPW was 9.2 months with atezolizumab plus bevacizumab versus 5.7 months with TACE (hazard ratio 0.67, p = 0.029). Adverse events (AEs), mostly hypertension, proteinuria, and malaise, were common. AEs requiring corticosteroids occurred in 10 patients (13.5%). Conclusion: Atezolizumab plus bevacizumab appears beneficial as first-line treatment for TACE-unsuitable patients with unresectable intermediate-stage unresectable HCC beyond up-to-seven criteria. Future strategies utilizing multimodal approaches may further improve outcomes.
科研通智能强力驱动
Strongly Powered by AbleSci AI